FIELD: chemistry.
SUBSTANCE: present invention relates to a compound of formula (Ia) or a pharmaceutically acceptable salt thereof
,
where in formula (Ia) R1 is phenyl, optionally substituted with a group selected from halogen, C1-6 alkyl and C1-6 alkyloxy; R2 is C1-3 alkyl, 5–6-membered heteroaryl containing 1 heteroatom selected from nitrogen, oxygen and sulphur, or phenyl, optionally substituted with a group selected from halogen, C1-6 alkyl and C1-6 alkyloxy; and Het is pyrazol-4-yl, as well as to a method of producing compounds of formula (Ia) and to a pharmaceutical composition containing a compound of formula (Ia).
EFFECT: there are prepared new compounds which can be used for treating cancer, such as human glioblastoma, human breast duct carcinoma, human liver and embryonic kidney carcinoma.
6 cl, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS | 2013 |
|
RU2666538C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
| ANTI-PROLIFERATIVE COMPOUNDS AND THEIR APPLICATIONS | 2019 |
|
RU2811969C2 |
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| EUROPIUM COMPLEX OF MONOSODIUM SALT OF 2,2ʹ,2ʹʹ,2ʹʹʹ-(2,2ʹ-((5ʹ-(4-AMINOPHENYL)-2,2ʹ-BIPYRIDINE-6-YL)METHYLAZADIYL)BIS-(ETHANE-2,1-DIYL))-BIS(AZATRIYL)TETRAACETIC ACID | 2020 |
|
RU2791044C2 |
| HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
| 1,2,4-TRIAZINE-3-AMINE DERIVATIVES | 2011 |
|
RU2771819C2 |
| DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | 2009 |
|
RU2514937C2 |
| INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | 2007 |
|
RU2474576C2 |
